NCT06507202 Comparison of Remimazolam and Propofol for Recovery of Ambulatory Upper Airway Surgery
| NCT ID | NCT06507202 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Chung-Ang University Gwangmyeong Hospital |
| Condition | Laryngeal Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 116 participants |
| Start Date | 2024-01-22 |
| Primary Completion | 2025-01-22 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 116 participants in total. It began in 2024-01-22 with a primary completion date of 2025-01-22.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to compare the effects of remimazolam and propofol on postoperative recovery time, complications, and safety in patients undergoing ambulatory upper airway surgery under general anesthesia.
Eligibility Criteria
Inclusion Criteria: * Adult patients (age 19 or older) undergoing ambulatory upper respiratory tract (nasal cavity, oral cavity, pharynx, larynx) surgery under general anesthesia * American Society of Anesthesiologists physical class classification I, II, and III Exclusion Criteria: * Patients who refused to participate in the study * Pregnant patients * Patients with a history of hypersensitivity to drugs or additives used during surgery * Patients with acute narrow-angle glaucoma * Alcohol or drug dependent patients * Patients with Child-Pugh class C liver dysfunction
Contact & Investigator
Se-Hee Min
STUDY CHAIR
Chung-Ang University Gwangmyeong Hospital
Frequently Asked Questions
Who can join the NCT06507202 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Laryngeal Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06507202 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06507202 currently recruiting?
Yes, NCT06507202 is actively recruiting participants. Contact the research team at seiheemin@gmail.com for enrollment information.
Where is the NCT06507202 trial being conducted?
This trial is being conducted at Gyeonggi-do, South Korea.
Who is sponsoring the NCT06507202 clinical trial?
NCT06507202 is sponsored by Chung-Ang University Gwangmyeong Hospital. The principal investigator is Se-Hee Min at Chung-Ang University Gwangmyeong Hospital. The trial plans to enroll 116 participants.